NEW YORK, NY--(Marketwired - Jun 5, 2013) - Levi & Korsinsky announces that a class action lawsuit has been commenced in the United States District Court for the Southern District of New York on behalf of investors who purchased Ventrus Biosciences, Inc. ("Ventrus" or the "Company") (
For more information, click here: http://zlk.9nl.com/ventrus-biosciences-vtus/.
The complaint alleges that during the Class Period, defendants issued materially false and misleading statements and omitted materially relevant facts regarding iferanserin (VEN 309) ("VEN 309"), the Company's chemical entity for the treatment of internal hemorrhoids. On June 25, 2012, Ventrus announced that VEN 309 had failed its Phase III trial before the FDA and that the Company was abandoning plans for further development of the treatment. In response to this news, the price of Ventrus common stock fell over 50% from a close of $12.26 on June 22, 2012 to a close of $5.02 per share on June 25, 2012.
If you suffered a loss in Ventrus you have until July 8, 2013 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. To obtain additional information, contact Joseph E. Levi, Esq. either via email at firstname.lastname@example.org or by telephone at (877) 363-5972, or visit http://zlk.9nl.com/ventrus-biosciences-vtus/.
Levi & Korsinsky is a national firm with offices in New York, New Jersey, and Washington D.C. The firm has extensive expertise in prosecuting securities litigation involving financial fraud, representing investors throughout the nation in securities and shareholder lawsuits. Attorney advertising. Prior results do not guarantee similar outcomes.